J&J posts earnings of $1.49 a share vs $1.45 expected

Analysts expected the company to post earnings per share of $1.45 on revenue of $17.45 billion, according to a Thomson Reuters consensus estimate. The company said Friday it has begun clinical trials for an Ebola vaccine in Sierra Leone as part of a new study being conducted in the nation's Kambia district, the site of some of the most recent cases.